免責事項: 本サイトは、FDA、ClinicalTrials.gov、PubMed、SEC EDGAR などの公式公開データを一般参考用に集約するものであり、医学的助言、診断、治療推奨、投資助言を構成しません。

臨床試験

Safety and Clinical Performance of a Biological Matrix Used in Abdominal Wall Reconstruction

NCT: NCT04580511 · ACTIVE_NOT_RECRUITING

NCT識別子NCT04580511
ステータスACTIVE_NOT_RECRUITING
開始日2020-11-04
SponsorMeccellis Biotech (INDUSTRY)
First posted
Last updated

概要

The general objective of the study is to confirm the medium/long-term safety and clinical performance of the CELLIS membrane used in abdominal wall reconstruction including, but not limited to, ventral hernia repair and stoma closure, and to identify emerging risks in comparison to the clinical data related to other types of fixation material. The present study will be a prospective multicentric non-randomized and noncontrolled trial involving 112 patients followed for 24 months. The study will be conducted in France in 3 investigational centres.

公式ソース

ClinicalTrials.govで見る →

データはClinicalTrials.gov APIから取得しています。最新のステータスは公式記録をご確認ください。

↑